Jundishapur Scientific Medical Journal

Jundishapur Scientific Medical Journal

Comparison of biological status of breast tumors in patients with metastatic and non -metastatic breast cancer who referred to Shahid Baqai Hospital

Document Type : Original Article

Authors
Atefeh Rezaee 1
Akram Ahangarpour 2
Roya Salehi Kahish 1
Saeed Bitaraf 3
Seyed Nematollah Jazayeri 4
Najmeh Aalmasi 5
1 Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Department of Physiology, Persian Gulf Physiology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Ahvaz,, Iran.
3 Department of Community Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Ahvaz,, Iran.
4 Department of Pathology. School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Ahvaz, Iran.
5 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
10.32592/jsmj.23.5.377
Abstract
Background and Objectives: Breast cancer is the most common malignant tumor in women worldwide and is divided into different subgroups based on histopathological and biological characteristics. This study aims to compare the biological status of breast tumors in patients with metastatic and non-metastatic breast cancer to assess the possibility of predicting metastatic and invasive types and to reduce the dangerous complications that may follow.
Subjects and Methods In this retrospective cross-sectional study, data from patients with breast cancer and metastatic breast cancer diagnosed within a two-year period from 2021 to 2023 were collected. The data included demographic information, types of biological receptors (ER, PR, Ki67, and Her-2), and survival status, all recorded in a questionnaire for analysis.
Results Her2-positive cases were 32.75 %( N=231) in the non-metastatic group and 34.38 %( N=68) in the metastatic group. Ki67 in the metastatic group was 33.8% low, 61.3% moderate, and 4.9% high, while in the second group it was 30.8% low and 69.2% moderate, with no high cases. ER-positive cases were 68.4% in the non-metastatic group and 70.8% in the metastatic group. PR-positive cases were 54.8% in the non-metastatic group and 56.9% in the metastatic group. Lymphadenopathy cases were 54.2% in the non-metastatic group and 69.0% in the metastatic group.
Conclusion no statistically significant differences between the clinical and biological characteristics of patients with and without metastasis. The distribution of various markers such as Her2, Ki67, ER, and PR was similar in both groups, and these markers cannot definitively predict the difference between patients with and without metastasis.
Keywords
Estrogen receptor breast cancer (ER)
progesterone receptor (PR)
human epidermal growth factor receptor-2 (HER2)
proliferation marker Ki-67
breast cancer
Subjects

  •  

    • Nardin S, Mora E, Varughese FM, D'Avanzo F, Vachanaram AR, Rossi V, Saggia C, Rubinelli S, Gennari A. Breast cancer survivorship, quality of life, and late toxicities. Frontiers in oncology. 2020 Jun 16;10:864. [3389/fonc.2020.00864 ] [PMID]
    • Bellanger M, Zeinomar N, Tehranifar P, Terry MB. Are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies?. Journal of global oncology. 2018 Jun 8. [1200/JGO.17.00207 ] [PMID]
    • Vaccarella S, Georges D, Bray F, Ginsburg O, Charvat H, Martikainen P, Brønnum-Hansen H, Deboosere P, Bopp M, Leinsalu M, Artnik B. Socioeconomic inequalities in cancer mortality between and within countries in Europe: a population-based study. The Lancet Regional Health–Europe. 2023 Feb 1;25. [1016/j.lanepe.2022.100551 ] [PMID]
    • Dolatkhah R, Hosseinalifam M, Sanaat Z, Dolatkhah N, Dastgiri S. Molecular Epidemiology of Breast Cancer in Iran: A Review Article. Journal of Obstetrics, Gynecology and Cancer Research. 2023 Sep 9;8(5):422-30.
    • Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. Jama. 2005 Mar 9;293(10):1245-56. [1001/jama.293.10.1245 ] [PMID]
    • Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021 Aug 15;127(16):3029-30. [1002/cncr.33587 ] [PMID]
    • Lakhani SR, Ellis IO, Schnitt S, Tan PH, van de Vijver M. WHO Classification of Tumours of the Breast. [1111/his.12463 ] [PMID]
    • Hussein MR, Abd‐Elwahed SR, Abdulwahed AR. Alterations of estrogen receptors, progesterone receptors and c‐erbB2 oncogene protein expression in ductal carcinomas of the breast. Cell Biology International. 2008 Jun;32(6):698-707. [1016/j.cellbi.2008.01.007 ] [PMID]
    • Phipps AI, Li CI. Breast cancer biology and clinical characteristics. Breast cancer epidemiology. 2010:21-46.
    • Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. American journal of clinical pathology. 2001 Jan 1;115(1):85-98. [1309/FDHX-L92R-BATQ-2GE0 ] [PMID]
    • Rakha EA, Patel A, Powe DG, Benhasouna A, Green AR, Lambros MB, Reis-Filho JS, Ellis IO. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. The American journal of surgical pathology. 2010 Oct 1;34(10):1472-9. [1097/PAS.0b013e3181f01916 ] [PMID]
    • Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long‐term follow‐up. Histopathology. 1992 Jun;20(6):479-89. [1111/j.1365-2559.1992.tb01032.x ] [PMID]
    • Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. New England Journal of Medicine.1985Jan17;312(3):146-51. [1056/NEJM198501173120303 ] [PMID]
    • Buerger H, Otterbach F, Simon R, Schäfer KL, Poremba C, Diallo R, Brinkschmidt C, Dockhorn‐Dworniczak B, Boecker W. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. The Journal of pathology. 1999 Dec;189(4):521-6. [1002/(SICI)1096-9896(199912)189:4<521::AID-PATH472>3.0.CO;2-B ] [PMID]
    • Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn‐Dworniczak B, Boecker W. Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways. The Journal of pathology. 1999 Mar;187(4):396-402. [1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L ] [PMID]
    • Gasparini G, Longo R, Torino F, Morabito A. Therapy of breast cancer with molecular targeting agents. Annals of oncology. 2005 May 1;16:iv28-36. [1093/annonc/mdi905 ] [PMID]
    • El-Yakub AI. Biological characteristics of breast cancers in a teaching hospital in Northwestern Nigeria. Sahel Medical Journal. 2020 Oct 1;23(4):211-4.
    • Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. Scientific Reports. 2021 Jul 2;11(1):13770.. [1038/s41598-021-92774-z ] [PMID]
    • Douganiotis G, Kesisis G, Lalla E, Korantzis I, Boukovinas I, Papazisis K. Prognostic significance of low HER2 expression in patients with metastatic hormone receptor-positive breast cancer treated with first line CDK4/6 inhibitors: a Greek multicenter real-world data analysis. Cancer Diagnosis & Prognosis. 2022 Sep;2(5):585. [21873/cdp.10146 ] [PMID]
    • Mohammed AA. Quantitative assessment of Ki67 expression in correlation with various breast cancer characteristics and survival rate; cross sectional study. Annals of Medicine and Surgery. 2019 Dec 1;48:129-34. [1016/j.amsu.2019.11.005 ] [PMID]
    • Li Y, Zhang X, Qiu J, Pang T, Huang L, Zeng Q. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis. J buon. 2019 Nov 1;24(6):2361-8. [PMID]
    • Peng L, Zhang Z, Zhao D, Zhao J, Mao F, Sun Q. Discordance in ER, PR, HER2, and Ki-67 expression between primary and recurrent/metastatic lesions in patients with primary early stage breast cancer and the clinical significance: retrospective analysis of 75 cases. Pathology and Oncology Research. 2021;27. [3389/pore.2021.599894 ] [PMID]
    • Grinda T, Joyon N, Lusque A, Lefèvre S, Arnould L, Penault-Llorca F, Macgrogan G, Treilleux I, Vincent-Salomon A, Haudebourg J, Maran-Gonzalez A. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. NPJ breast cancer. 2021 Apr 16;7(1):41.[ 1038/s41523-021-00252-6 ] [PMID]
    • Hu X, Chen W, Li F, Ren P, Wu H, Zhang C, Gu K. Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic

     

    • breast cancer and its clinical significance. Frontiers in Oncology.2023Apr28;13:1053125. [3389/fonc.2023.1053125 ] [PMID]
    • Mamoor S. The gene encoding the estrogen receptor, ESR1, is differentially expressed in the primary tumors and metastases of patients with breast cancer based on survival outcomes and its expression correlates with survival.
    • Chen R, Qarmali M, Siegal GP, Wei S. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution. Modern Pathology. 2020 Dec 1;33(12):2499-506. [1038/s41379-020-0615-z ] [PMID]
    • Singh D, Mandal A. The prognostic value of lymph node ratio in survival of non-metastatic breast carcinoma patients. Breast Cancer Research and Treatment. 2020 Dec;184:839-48. [1007/s10549-020-05885-y ] [PMID]
    • Leonardi MC, Arrobbio C, Gandini S, Volpe S, Colombo F, La Rocca E, Galimberti V, Kahler-Ribeiro-Fontana S, Fodor C, Dicuonzo S, Rojas DP. Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. Radiotherapy and Oncology. 2021 Oct 1;163:128-35. [1016/j.radonc.2021.08.013 ] [PMID]

     

Jundishapur Scientific Medical Journal
Volume 23, Issue 5 - Serial Number 152
September and October 2024
Pages 377-390

  • Receive Date 20 July 2024
  • Revise Date 06 August 2024
  • Accept Date 12 August 2024